OPT.ASX: Reinstatement to ASX and Update on LAM Development Program

Reinstatement to ASX and Update on LAM Development Program

Stock	Opthea Ltd (OPT.ASX)
Release Time	3 Jun 2026, 8:48 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Opthea Announces Reinstatement to ASX and LAM Development Update

Key Points

Reinstatement to ASX expected on or around 03 June 2026
Focus on OPT-302 for lymphangioleiomyomatosis (LAM) treatment
Three-stage development program planned over 18 months

Full Summary

Opthea Ltd. is pleased to announce the reinstatement of its securities trading on the Australian Securities Exchange (ASX) on or around 03 June 2026. The company has refocused its strategy on advancing OPT-302 for the treatment of lymphangioleiomyomatosis (LAM), a rare, chronic lung disease that primarily affects women. LAM is characterized by elevated levels of VEGF-C and VEGF-D, which OPT-302 is designed to inhibit. The company has initiated a three-stage development program over an anticipated 18-month period to assess the potential application of OPT-302 in LAM. The program includes preclinical biology and inhalation studies, early human pharmacodynamic and tolerability data, and clinical proof-of-concept in LAM patients. Opthea believes it has sufficient working capital to pursue its objectives for at least 18 months.

Guidance

Opthea expects to require approximately A$13.1 million for its LAM development program and other expenses over 18 months.

Outlook

Opthea aims to evaluate OPT-302 in patients with LAM to assess preliminary signals of biological and clinical activity, with endpoints expected to include measures of lung function and lymphatic-related outcomes relevant to LAM.